Spondyloarthritis & psoriatic arthritis
Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries
Authors' conclusion
Baseline predictors of remission, response and adherence to TNFi therapy were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalizable from country level to disease level.
Study context
- Population
- Bio-naïve patients with PsA initiating a first TNF inhibitor (TNFi), 13 European registriespooled cohort
- Participants
- 13,369 patients
- Outcome
- Baseline predictors of DAPSA28 remission
- Follow-up
- 6 months
Methodological detailspooled analysis of 13 European registries, multicentre, logistic regression on multiply imputed data, pooled and per-registry analyses
- Pooled analysis of 13 European registries
- Multicentre
- Logistic regression on multiply imputed data
- Pooled and per-registry analyses
Performance
As reported in the abstract
Baseline predictors of DAPSA28 remission (OR)
- DAPSA28 remission proportion (n = 6954 with data)
- 25%
- Age, per year: OR
- 0.97 (0.96-0.98) (95% CI)
- Disease duration 2-3 years vs <2 years: OR
- 1.20 (0.89-1.60) (95% CI)
- Disease duration 4-9 years vs <2 years: OR
- 1.42 (1.09-1.84) (95% CI)
- Disease duration ≥10 years vs <2 years: OR
- 1.66 (1.26-2.20) (95% CI)
- Men vs women: OR
- 1.85 (1.54-2.23) (95% CI)
- CRP >10 vs ≤10 mg/l: OR
- 1.52 (1.22-1.89) (95% CI)
- Patient fatigue score, per 1 mm increase: OR
- 0.99 (0.98-0.99) (95% CI)
Further findings
DAPSA28 moderate response proportion · 6 months
- Moderate response (n = 5275 with data)
- 34%
Drug retention proportion · 12 months
- 12-month drug retention (n = 13 369)
- 63%
Common predictors across all three outcomes
- Common baseline predictors of remission, moderate response and 12-month drug retention identified
- 5
Original publication
Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries. Rheumatology (Oxford). Published 14 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →